Home Newsfeeds Oppenheimer Downgrades Edwards Lifesciences to Perform

Oppenheimer Downgrades Edwards Lifesciences to Perform

Oppenheimer analyst Suraj Kalia downgrades Edwards Lifesciences (NYSE:EW) from Outperform to Perform.

byBenzinga Newsdesk

October 28, 2022

1 minute read

Oppenheimer analyst Suraj Kalia downgrades Edwards Lifesciences (NYSE:EW) from Outperform to Perform.

Reddit Users See An ‘Inverse Moment’ As Shares Pop 14% On Social Media Platform’s Financial Performance

By Surbhi Jain

May 8, 3:05 PM

Reddit beat expectations, with revenue of $243 million; ad revenue was up 39%. Analysts are optimistic about its potential for profitability.

RDDT

Stephens & Co. Maintains Overweight on Glaukos, Lowers Price Target to $68

By Benzinga Newsdesk

December 28, 9:08 AM

Stephens & Co. analyst George Sellers maintains Glaukos (NYSE:GKOS) with a Overweight and lowers the price target from $69 to $68.

GKOS

Morgan Stanley Maintains Overweight on CinCor Pharma, Raises Price Target to $45

By Benzinga Newsdesk

August 9, 9:19 AM

Morgan Stanley analyst Jeffrey Hung maintains CinCor Pharma (NASDAQ:CINC) with a Overweight and raises the price target from $31 to $45.

CINC

EXCLUSIVE: Biden Administration ‘Let The SEC Go Unchecked,’ Tether Co-Founder Says

By Murtuza Merchant

June 14, 8:33 AM

The Joe Biden administration has let the SEC go unchecked, Tether (CRYPTO: USDT) co-founder William Quigley on Friday said, has he expressed strong concerns about the current

$USDT

Oppenheimer Downgrades Edwards Lifesciences to Perform

Related Posts

Reddit Users See An ‘Inverse Moment’ As Shares Pop 14% On Social Media Platform’s Financial Performance

Stephens & Co. Maintains Overweight on Glaukos, Lowers Price Target to $68

Morgan Stanley Maintains Overweight on CinCor Pharma, Raises Price Target to $45

EXCLUSIVE: Biden Administration ‘Let The SEC Go Unchecked,’ Tether Co-Founder Says